Ardelyx (ARDX) Stock Price, News & Analysis

Company Overview

Ardelyx, Inc. (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders. The company is advancing RDX8940, a non‐systemic, gut‐restricted TGR5 agonist intended for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. Additional programs focus on novel mechanisms to manage uremic toxins and intestinal sodium balance, reinforcing Ardelyx’s emphasis on gut‐targeted therapies that may improve patient outcomes without the safety risks of systemic drug exposure.

Founded in 2010 and headquartered in San Mateo, California, Ardelyx operates research and development facilities in the Bay Area, with a commercial infrastructure supporting product launch and patient access in the United States. The company has forged strategic collaborations—most notably with Mitsubishi Tanabe Pharma in Japan for the development and commercialization of tenapanor. Ardelyx’s leadership team, led by President and Chief Executive Officer Michael A. Raab, combines experience in drug discovery, regulatory affairs and commercial operations to drive its mission of bringing new treatment options to patients with high unmet medical needs.

Key Stats

• Today's Range: $5.00 to $5.16
• 50-Day Range: $4.24 to $6.68
• 52-Week Range: $3.21 to $6.78
• Volume: 1.79 million shs
• Average Volume: 4.49 million shs
• Market Capitalization: $1.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.70
• Consensus Rating: Moderate Buy

Ardelyx Stock Analysis - MarketRank™

Ardelyx scored higher than 86% of companies evaluated by MarketBeat, and ranked 138th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ardelyx has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Ardelyx has a consensus price target of $11.70, representing about 129.2% upside from its current price of $5.11.

Amount of Analyst Coverage

Ardelyx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ardelyx are expected to grow in the coming year, from ($0.18) to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ardelyx is -22.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ardelyx is -22.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ardelyx has a P/B Ratio of 6.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.20% of the outstanding shares of Ardelyx have been sold short.

Short Interest Ratio / Days to Cover

Ardelyx has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Ardelyx has recently decreased by 7.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ardelyx does not currently pay a dividend.

Dividend Growth

Ardelyx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.32

Percentage of Shares Shorted

8.20% of the outstanding shares of Ardelyx have been sold short.

Short Interest Ratio / Days to Cover

Ardelyx has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Ardelyx has recently decreased by 7.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.65

News Sentiment

Ardelyx has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Ardelyx this week, compared to 7 articles on an average week.

Search Interest

26 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 136% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $996,917.00 in company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Ardelyx is held by insiders.

Percentage Held by Institutions

58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARDX Stock Analysis - Frequently Asked Questions

How have ARDX shares performed this year?

Ardelyx's stock was trading at $5.07 at the beginning of 2025. Since then, ARDX stock has increased by 0.7% and is now trading at $5.1050.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) issued its quarterly earnings results on Monday, August, 4th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The business's quarterly revenue was up 23.0% on a year-over-year basis.
Read the conference call transcript.

Who are Ardelyx's major shareholders?

Top institutional shareholders of Ardelyx include Voya Investment Management LLC (0.02%). Insiders that own company stock include David M Mott, Michael Raab, Justin A Renz, Laura A Williams, Susan Rodriguez, Robert Blanks, Elizabeth A Grammer, Eric Duane Foster, Mike Kelliher, David P Rosenbaum and Robert Ora Felsch.
View institutional ownership trends.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), GE Aerospace (GE), Builders FirstSource (BLDR) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARDX
• CIK: 1437402
• Web: www.ardelyx.com
• Phone: (510) 745-1700
• Fax: 510-745-0493
• Employees: 90
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Ardelyx: $11.70
• High Price Target: $15.00
• Low Price Target: $8.00
• Potential Upside/Downside: +131.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.14 million
• Net Margins: -14.60%
• Pretax Margin: -14.36%
• Return on Equity: -36.57%
• Return on Assets: -13.42%

Debt

• Debt-to-Equity Ratio: 1.44
• Current Ratio: 4.30
• Quick Ratio: 4.03

Sales & Book Value

• Annual Sales: $333.61 million
• Price / Sales: 3.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 6.93

Miscellaneous

• Outstanding Shares: 240,980,000
• Free Float: 229,416,000
• Market Cap: $1.22 billion
• Optionable: Optionable
• Beta: 0.67